2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1362

Investigating the Role of Dendritic Cell Maturation & T Cell Activation within the Inflamed Synovium in Rheumatoid Arthritis
Abstract Number: 1363

Changes in Cyclooxygenase-2’s Expression, and PGE2’s and 6-Keto-PGF1α Levels in the Presence of the Muscarinic Acethylcholine Receptor Antibody in Primary Sjogren Syndrome
Abstract Number: 1364

Treating Experimental Arthritis with the Innate Immune Inhibitor IL-37 Reduces Joint and Systemic Inflammation
Abstract Number: 1365

Innate Lymphoid Cells. New Players in Systemic Sclerosis Correlate with Extent of Skin and Lung Fibrosis
Abstract Number: 1366

Natural Antibodies, Not B Cells, Contribute to Acute Cell Death-Induced Inflammation
Abstract Number: 1367

Fibroblast-like Synoviocytes Shape and Perpetuate the Inflammatory Immune Responses Associated with Antibiotic-Refractory Lyme Arthritis.
Abstract Number: 1368

PMN Reactivity Contribute to Acute Onset Joint Inflammation By Increasing CXCL8 Production in Joints of RA Patients with Anti-Collagen II Antibodies
Abstract Number: 1369

Enhanced Myelopoiesis Downstream of Toll-like Receptor 9 Activation Drives a Feed-Forward Inflammatory Response
Abstract Number: 1370

CD40/CD40L Pathway Is Associated with Increased Oxidative Burst and Neutrophil Extracellular Traps Release in Behcet´s Disease
Abstract Number: 1371

Complement-Mediated Neutrophil Lysis-a Mechanism Promoting Hypercitrullination in Rheumatoid Arthritis?
Abstract Number: 1372

Characterization of Synovial Mast Cells in Knee Osteoarthritis: Association with Clinical Parameters
Abstract Number: 1373

Epigenetic Mechanisms Contribute to the Lack of LPS-Induced Tolerance in Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 1374

Mucosal-Associated Invariant T- Cells Are Decreased and Functionally Immature in Peripheral Blood of Patients with Primary Sjögren Syndrome
Abstract Number: 1375

S100A8/A9, a Serum and Imaging Biomarker for Assessing Joint Inflammation and Destruction in Experimental Seronegative Arthritis
Abstract Number: 1376

Presence of the Interferon Signature in Anti-Nuclear Antibody Positive Individuals Prior to the Onset of Systemic Autoimmune Rheumatic Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].